期刊文献+

p57^(kip2) mRNA在肝细胞癌发生过程中的表达

Expression of p57^(kip2) mRNA in Human Hepatocarcinogenesis
暂未订购
导出
摘要 目的研究p57kip2 mRNA在人体肝细胞癌发生不同阶段的表达状况,探讨与肝癌发生发展及分化的关系.方法采用原位分子杂交技术检测正常肝组织、慢性肝炎、肝硬化、癌周肝硬化和肝细胞癌共42例标本中p57kip2 mRNA的表达.结果正常肝组织组未见p57kip2 mRNA表达,慢性肝炎组阳性表达率为57.14%(4/7),肝硬化组阳性表达率为40.00%(4/10),癌周肝硬化组与肝癌组阳性表达率分别为70.00%(7/10)和20.00%(2/10).肝癌组p57kip2 mRNA阳性表达率明显下降,与癌周肝硬化组差异有统计学意义(P<0.05).肝癌组分化好者与分化差者表达差异有统计学意义(P<0.05).结论p57kip2 mRNA表达下降在原发性肝癌的发生发展中起着重要作用,且可能与肝癌的分化有关. Objective To study the expression of p57^kip2 mRNA during different phases genesis and to explore their relationships with the occurrence, development and differentiation of Methods In situ hybridization (ISH) for p57^kip2 mRNA was performed in formalin -fixed and of hepatocarcino- hepatocarcinoma. paraffin - embedded sections in 88 cases of normal liver tissue (n = 10), chronic hepatitis (n = 18), liver cirrhosis (n =20), paracancerous cirrhosis (n = 18) and hepatocellular carcinoma (n = 22). Results The positive rate of p57^kip2 mRNA was 57. 14% (4/7) in chronic hepatitis, 40. 00% (4/10) in liver cirrhosis, 70. 00% (7/10) in paratumor cirrhosis and 20. 00% (2/10) in hepatocellular carcinoma respectively. The expression of p57^kip2 mRNA in paratumor cirrhosis was significantly higher than that in hepatocellular carcinoma ( P 〈 0. 05 ). And there was statistical difference of the expression of p57^kip2 mRNA between well differentiated hepatocellular carcinoma and that of poorly differentiated hepatocellular carcinoma (P 〈 0. 05). Conclusion The decrease of p57^kip2 mRNA in hepatocellular carcinoma indicates that p57^kip2 may be involved in human hepatocarcinogenesis and its differentiation.
出处 《昆明医学院学报》 CAS 2007年第3期10-12,24,共4页 Journal of Kunming Medical College
基金 云南省自然科学基金资助(2000C0058M 2005C0045M)
关键词 肝细胞癌 肝炎 肝硬化 P57^KIP2 原位杂交 Hepatocellular carcinoma Hepatitis Liver cirrhosis p57^kip2 mRNA In situ hybridization
  • 相关文献

参考文献2

二级参考文献45

  • 1Zhao-You Tang Liver Cancer Institute & Zhongshan Hospital of Fudan University Professor of Surgery Chairman.Liver Cancer Institute of Fudan University(previous Liver Cancer Institute of Shanghai Medical University)136 Yixueyuan Road,Zhongshan Hospital,Shanghai 200032,China..Hepatocellular Carcinoma-Cause,Treatment and Metastasis[J].World Journal of Gastroenterology,2001,7(4):445-454. 被引量:214
  • 2王东,史景泉.肝细胞癌增殖细胞核抗原免疫组化研究[J].癌症,1996,15(2):112-114. 被引量:6
  • 3张新立,史景泉,王晓东,王东.人肝细胞癌与癌旁肝细胞增殖活性的定量研究[J].第三军医大学学报,1996,18(1):36-39. 被引量:1
  • 4Clurman BE, Roberts JM. Cell cycle and cancer. J Natl Cancer Inst 1995; 87:1499-1504.
  • 5Grana X, Reddy EP. Cell cycle control in mammalian cells:role of cyclins, cyclin dependent kinase(CDKs), growth suppressor and cyclin dependent kinase inhibitors(CDKIs).Oncogene 1995; 11:211-219.
  • 6Sherr CJ. G1 phase progression :cyclin on cue. Cell 1994; 79:551-555.
  • 7Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-1677.
  • 8Kamb A. Cell-cycle regulators and cancer. Trends Genet 1995;11:136-140.
  • 9Hunter T, Pines J. Cyclins and cancer Ⅱ: CyclinD and CDK inhibitors come of age. Cell 1994; 79:573-582.
  • 10Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K,Tavtigian SV, Stockent E, Day RS 3rd, Johon BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-440.

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部